Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 6/20 | 0.81 |
| ▸ | NR1H2 | P55055 | 10/20 | 0.69 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.69 |
| ▸ | SOD1 | P00441 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24177920 | 1.00 | POLA1 (0.81) | POLA1NR1H2NR1H3SOD1CYP3A4 | |
| SCHEMBL19786219 | 1.00 | POLA1 (0.81) | POLA1NR1H2NR1H3SOD1CYP3A4 | |
| SCHEMBL19770990 | 1.00 | POLA1 (0.81) | POLA1NR1H2NR1H3SOD1CYP3A4 | |
| SCHEMBL12292033 | 1.00 | POLA1 (0.81) | POLA1NR1H2NR1H3SOD1CYP3A4 | |
| SCHEMBL25873377 | 0.91 | POLA1 (0.68) | POLA1NR1H2NR1H3SOD1CYP3A4 | |
| SCHEMBL19785805 | 0.90 | NR1H2 (0.69) | POLA1NR1H2NR1H3SOD1CYP3A4 | |
| SCHEMBL280198 | 0.89 | POLA1 (1.00) | POLA1NR1H2NR1H3CYP3A4CYP2C9 | |
| SCHEMBL12872352 | 0.89 | POLA1 (1.00) | POLA1NR1H2NR1H3CYP3A4CYP2C9 | |
| SCHEMBL5510769 | 0.89 | POLA1 (1.00) | POLA1NR1H2NR1H3CYP3A4CYP2C9 | |
| SCHEMBL29295275 | 0.87 | POLA1 (0.62) | POLA1NR1H2NR1H3SOD1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932238-B2 | Graphene and graphene oxide nano-environments for chemical reactions and atomic reformations | PEERLESS WORLDWIDE, LLC (US) | 2018-04-03 | — | — | US | disclosed |
| US-20150307971-A1 | GRAPHENE AND GRAPHENE OXIDE NANO-ENVIRONMENTS FOR CHEMICAL REACTIONS AND ATOMIC REFORMATIONS | PEERLESS WORLDWIDE, LLC (US) | 2015-10-29 | — | — | US | disclosed |
| US-9023308-B2 | Facile synthesis of graphene, graphene derivatives and abrasive nanoparticles and their various uses, including as tribologically-beneficial lubricant additives | PEERLESS WORLDWIDE, LLC (US) | 2015-05-05 | — | — | US | disclosed |
| US-8865113-B2 | Facile synthesis of graphene, graphene derivatives and abrasive nanoparticles and their various uses, including as tribologically-beneficial lubricant additives | PEERLESS WORLDWIDE, LLC (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140227211-A1 | FACILE SYNTHESIS OF GRAPHENE, GRAPHENE DERIVATIVES AND ABRASIVE NANOPARTICLES AND THEIR VARIOUS USES, INCLUDING AS TRIBOLOGICALLY-BENEFICIAL LUBRICANT ADDITIVES | PEERLESS WORLDWIDE, LLC (US) | 2014-08-14 | — | — | US | disclosed |
| US-20140134092-A1 | FACILE SYNTHESIS OF GRAPHENE, GRAPHENE DERIVATIVES AND ABRASIVE NANOPARTICLES AND THEIR VARIOUS USES, INCLUDING AS TRIBOLOGICALLY-BENEFICIAL LUBRICANT ADDITIVES | SHANKMAN RICHARD S (US) | 2014-05-15 | — | — | US | disclosed |
| EP-0806411-B1 | Anti-viral compounds | LILLY CO ELI (US) | 2001-07-11 | — | — | EP | disclosed |
| EP-0806409-B1 | Anti-viral compounds | LILLY CO ELI (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-0811599-B1 | Anti-viral compounds | LILLY CO ELI (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6180816-B1 | COMPOUNDS WHICH ABROGATE HEMAGGLUTININ-MEDIATED FUSION OF VIRUS-HOST MEMBRANES; TREATING INFLUENZA | ELI LILLY AND COMPANY | 2001-01-30 | — | — | US | disclosed |
| EP-0806408-B1 | Anti-viral compounds | LILLY CO ELI (US) | 2000-12-13 | — | — | EP | disclosed |
| US-6127422-A | INHIBITING AN ENVELOPE VIRUS SELECTED FROM THE GROUP CONSISTING OF INFLUENZA BOVINE DIARRHEAL, HEPATITIS C AND TICK BORNE ENCEPHALITIS VIRUS THAT UNDERGOES HEMAGGLUTININ MEDIATED FUSION WITH A HOST CELL; PHENANTHRENE ESTERS | ELI LILLY AND COMPANY (US) | 2000-10-03 | — | — | US | disclosed |
| US-6124494-A | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| US-6103922-A | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 2000-08-15 | — | — | US | disclosed |
| US-6096917-A | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0811599-A2 | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 1997-12-10 | — | — | EP | disclosed |
| EP-0806411-A2 | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 1997-11-12 | — | — | EP | disclosed |
| EP-0806203-A2 | Anti-viral compositions | ELI LILLY AND COMPANY (US) | 1997-11-12 | — | — | EP | disclosed |
| EP-0806409-A1 | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 1997-11-12 | — | — | EP | disclosed |
| EP-0806408-A1 | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 1997-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227211-A1 | FACILE SYNTHESIS OF GRAPHENE, GRAPHENE DERIVATIVES AND ABRASIVE NANOPARTICLES AND THEIR VARIOUS USES, INCLUDING AS TRIBOLOGICALLY-BENEFICIAL LUBRICANT ADDITIVES | GRN, CCNO, TELO2 | POLA1 232/4885NR1H2 2316/4885NR1H3 2486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.